Literature DB >> 23428865

Expression of E-cadherin and vascular endothelial growth factor in noncancerous liver is associated with recurrence of hepatocellular carcinoma after curative resection.

Mutsuko Minata1, Masatoshi Kudo, Kouji H Harada, Iwao Ikai, Naoshi Nishida.   

Abstract

OBJECTIVES: Hepatocellular carcinoma (HCC) frequently recurs even after curative resection. The purpose of this study was to examine how background liver affects postoperative recurrence of HCC that underwent curative resection using expression of cancer-related molecules in the adjacent noncancerous liver of HCC patients.
METHODS: We examined expression of E-cadherin and vascular endothelial growth factor in noncancerous liver tissues of 133 HCC patients who underwent curative resection of tumors using immunohistochemical analysis. Associations between expressions of these molecules and disease-free survival of HCC were analyzed using the Kaplan-Meier method.
RESULTS: The average period of follow-up of the patients was 6.7 years. Multivariate analyses revealed that low platelet count and negative expression of E-cadherin in adjacent noncancerous liver were significantly associated with metastatic recurrence [p = 0.017, hazard ratio (HR) = 1.31 for low platelet count, and p = 0.009, HR = 1.43 for negative expression of E-cadherin, respectively].
CONCLUSIONS: Expression levels of E-cadherin in adjacent noncancerous liver after surgical resection was associated with metastatic HCC recurrence later on. Analysis of E-cadherin expression should provide important information for predicting recurrence after curative resection of HCC.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428865     DOI: 10.1159/000345896

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  EGR1 mediates miR-203a suppress the hepatocellular carcinoma cells progression by targeting HOXD3 through EGFR signaling pathway.

Authors:  Lumin Wang; Hongfei Sun; Xiaofei Wang; Ni Hou; Lingyu Zhao; Dongdong Tong; Kang He; Yang Yang; Tusheng Song; Jun Yang; Chen Huang
Journal:  Oncotarget       Date:  2016-07-19

Review 3.  The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Qing Pang; Kai Qu; Jing-Yao Zhang; Si-Dong Song; Su-Shun Liu; Ming-Hui Tai; Hao-Chen Liu; Chang Liu
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.